Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Adding This to DIPSS Helps HCT Outcome Prediction
Biol Blood Marrow Transplant; ePub 2017 Sep 29; Bannow, et al
Adding cytogenetics, thrombocytopenia, and red cell transfusion dependence as risk factors appears to improve the Dynamic International Prognostic Scoring System (DIPSS), according to a study involving 233 individuals with myelofibrosis (MF). Investigators sought to determine if the enhanced system would predict post- hematopoietic cell transplantation (HCT) outcomes better than DIPSS-alone. Among the results:
- 5-year overall survival rate for patients with low/int-1 risk MF was 78%.
- Relapse and treatment-related mortality rates were 5% and 20%, respectively.
- 5-year overall survival rate in patients with high-risk MF was 35%.
- Relapse and treatment-related mortality rates were 28% and 40%, respectively.
- HCT-comorbidity index of ≥3 was linked with higher non-relapse and overall mortality, and lower relapse-free survival.
- Older patients were 3 times more likely to experience relapse.
- At a median follow-up of 8 years, ~half of patients had survived.
The authors noted that the findings may help improve the ability to advise patients about transplant timing.
Bannow B, Salit R, Storer B, et al. Hematopoietic cell transplantation for myelofibrosis: DIPSS plus risk predicts post-transplant outcomes. [Published online ahead of print September 29, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.09.016.